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Abstract 
Background: An autoimmune disease is characterized by tissue damage, caused by self-reactivity of different effec-
tor mechanisms of the immune system, namely antibodies and T cells. All autoimmune diseases, to some extent, 
have implications for fertility and obstetrics. Currently, due to available treatments and specialised care for pregnant 
women with autoimmune disease, the prognosis for both mother and child has improved significantly. However 
these pregnancies are always high risk. The purpose of this study is to analyse the fertility/pregnancy process of 
women with systemic and organ-specific autoimmune diseases and assess pathological and treatment implications.
Methods: The authors performed an analysis of the clinical records and relevant obstetric history of five patients 
representing five distinct autoimmune pathological scenarios, selected from Autoimmune Disease Consultation at 
the Hospital of Braga, and reviewed the literature.
Results: The five clinical cases are the following: Case 1–28 years old with systemic lupus erythematosus, and clini-
cal remission of the disease, under medication with hydroxychloroquine, prednisolone and acetylsalicylic acid, with 
incomplete miscarriage at 7 weeks of gestation without signs of thrombosis. Case 2–44 years old with history of two 
late miscarriages, a single preterm delivery (33 weeks) and multiple thrombotic events over the years, was diagnosed 
with antiphospholipid syndrome after acute myocardial infarction. Case 3–31 years old with polymyositis, treated 
with azathioprine for 3 years with complete remission of the disease, took the informed decision to get pregnant after 
medical consultation and full weaning from azathioprine, and gave birth to a healthy term new-born. Case 4–38 years 
old pregnant woman developed Behcet’s syndrome during the final 15 weeks of gestation and with disease exac-
erbation after delivery. Case 5–36 years old with autoimmune thyroiditis diagnosed during her first pregnancy, with 
difficult control over the thyroid function over the years and first trimester miscarriage, suffered a second miscarriage 
despite clinical stability and antibody regression.
Conclusions: As described in literature, the authors found a strong association between autoimmune disease and 
obstetric complications, especially with systemic lupus erythematosus, antiphospholipid syndrome and autoimmune 
thyroiditis.
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Background
An autoimmune disease (AID) is characterised by tissue 
damage, caused by self-reactivity of different effectors 
mechanisms of the immune system, namely antibodies 
and T cells. Its occurrence may be associated with genetic 
and/or environmental predisposition. There is an activa-
tion of the adaptive immune response with tissue damage 
and inflammation in the absence of any infection, expo-
sure to toxins or tumour growth [1]. Although, individu-
ally, each AID affects a small number of individuals, as a 
whole, it is estimated that its prevalence is between 7.6 
and 9.4% [2]. All AIDs, to some extent, have implications 
for fertility and obstetrics. In the general population, 
about 80% of miscarriages occur in the first 12 weeks of 
pregnancy and the risk of miscarriage in those under the 
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age of 35 is about 10% while it is about 45% in those over 
the age of 40 [3].
Pregnancy and AID
Most AIDs occur frequently in women and should they 
appear at childbearing age, they pose a potential risk for 
almost all aspects of reproduction, from fertility to preg-
nancy itself (Table 1) [4–8]. In the past, it was suggested 
that women with certain AIDs [particularly systemic 
lupus erythematosus (SLE)/antiphospholipid syndrome 
(APS)] should avoid pregnancy. Currently, due to avail-
able treatments and specialised care for pregnant women 
with AID, the prognosis for both mother and child has 
improved significantly [4, 7, 9]. However, these pregnan-
cies are always high risk, often associated with foetal loss 
in the first trimester, preeclampsia/eclampsia, intrauter-
ine growth restriction, premature rupture of membranes, 
placental insufficiency, pre-term birth, caesarean deliv-
ery and low birth weight [4, 5, 9]. The overall principle, 
common to all AIDs, is planning the pregnancy for the 
remission phase of the disease, in addition to all the care 
necessary for a successful pregnancy [9].
Goal
The purpose of this study is to analyse the fertility/preg-
nancy process of women with AID and assess the patho-
logical and treatment implications.
Systemic AIDs
Systemic lupus erythematosus
SLE is a complex AID with varied clinical manifestations 
and developments. It is characterised by the presence of 
antinuclear autoantibodies (ANA), anti-DNA, anti-RNA, 
anti-Ro/SSA and anti-La/SSB autoantibodies (among oth-
ers), immune complex deposition and damages to target 
organs, especially kidneys, skin and joints. It is associated 
with a significant mortality rate [10]. Immunological mech-
anisms involved include defects in the removal of immune 
complexes, apoptosis and antigen presentation. The treat-
ment may be topical (sunscreen and corticosteroids) or 
systemic, with anti-inflammatory drugs (non-steroidal 
anti-inflammatory drugs, salicylates) or immunosuppres-
sors (hydroxychloroquine, methotrexate, corticosteroids, 
cyclophosphamide, mycophenolate mofetil, azathioprine, 
biological therapy) [11].
Antiphospholipid syndrome
APS is defined by the presence of at least one clinical 
manifestation (venous/arterial thrombosis or obstetric 
complications) and antiphospholipid antibodies (aAP). 
aAPs are part of a set of antibodies that recognise nega-
tively charged plasma proteins and include anti-cardi-
olipin, anti-β-2 glycoprotein and lupus anticoagulant 
antibodies, among others [4]. It also causes skin and 
cardiac valves lesions and changes in neurological, renal 
and haematological functions [12]. This syndrome can 
be primary or occur in association with other systemic 
diseases, especially SLE [9]. Many individuals are aAP 
positive without presenting any symptoms and may 
develop this syndrome. The prevention of the morbid-
ity associated with APS requires an assessment of the 
risk of thrombosis and the evaluation of the benefits of 
antithrombotic therapy, which must be performed indi-
vidually, taking into account the immunological profile 
and background [12].
Polymyositis (PM)/dermatomyositis (DM)
Polymyositis with/without dermatomyositis is an 
inflammatory myopathy which begins by symmetri-
cally affecting the proximal muscles, is characterised 
by an increase in the levels of muscle enzymes (creatine 
kinase/aldolase), electrophysiological changes and char-
acteristic histological findings. These myopathies may 
involve the muscles that control breathing and swallow-
ing, the heart (pericarditis, cardiomyopathy and heart 
failure) or the lungs (complications arising from aspi-
ration, interstitial lung disease and pulmonary hyper-
tension). DM also includes skin changes. While PM is 
mediated by T cells (CD8+), DM is a vascular disorder, 
mediated by autoantibodies. The first-line treatment of 
PM/DM is corticosteroid therapy, and it may call for 
the administration of other immunosuppressive drugs 
Table 1 Available information on fertility and miscarriage rates in autoimmune diseases (adapted from Carp et al. [5])
aAP antiphospholipid antibodies.
Disease Fertility Miscarriage
Antiphospolipidic syndrome New tudies suggest a role played by aAP in infertility 
pathogenesis
Reported recurrent foetal loss with a 10–19% frequency
Autoimmune thyroiditis Antibodies associated with increased risk of infertility Antibodies associated with increased risk of miscarriages 
(recurrent)
Systemic lupus erythematosus No increased risk of infertility aAP are the main miscarriage risk factor and are present 
in 34%
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(azathioprine or methotrexate), to which DM responds 
better [1].
Vasculitis
Vasculitis, an immune-mediated disease, is potentially 
fatal, especially when it affects medium or large calibre 
vessels. On the one hand, it can cause aneurysms, rup-
tures and haemorrhages and on the other, it may lead 
to luminal stenosis with obstruction, tissue ischemia or 
infarction. There are three major categories of systemic 
vasculitis: large-, medium- and small-vessel vasculitis. Its 
accurate diagnosis is difficult and requires clinical, patho-
logical and laboratory data, crucial for an appropriate 
diagnosis and therapy [11].
Behcet’s disease (BD) is a multisystem vasculitis, char-
acterised by orogenital ulcers, uveitis and skin lesions. It 
may also affect the gastrointestinal tract, joints, the cen-
tral nervous system or the cardiovascular system. Venous 
or arterial thrombosis may occur due to endothelial dys-
function and hypercoagulability. Its diagnosis is primar-
ily clinical, although a positive Pathergy test is a classic 
indicator of the disease. Its treatment differs and may 
be topical (corticosteroids) or systemic (corticosteroids, 
anti-TNF-α) [13–15].
Organ‑specific AIDs
Autoimmune thyroiditis (AIT)
90% of non-iatrogenic hypothyroidism in countries with-
out iodine deficiency occurs due to autoimmunity and it 
is a prevalent condition in women of childbearing age [1, 
5, 16]. There are several types of AITs, of which the most 
noteworthy is Hashimoto’s thyroiditis, characterised by 
the presence of high levels of antithyroglobulin and anti-
thyroid peroxidase antibodies in the presence of hypo-
thyroidism. Available treatment consists of hormone 
replacement with exogenous thyroxin.
Methods
The authors performed a systematic literature review and 
an analysis of the clinical records and relevant obstetric 
history of 5 patients with AID, representing five distinct 
AID pathological scenarios, selected from AID Consulta-
tion at the Hospital of Braga.
Results and discussion
The following are the descriptions and analysis of a series 
of five clinical cases.
Case 1: systemic lupus erythematosus
A 28 years old Brazilian citizen was diagnosed with SLE 
in 2010 after the appearance of osteoarticular, vascular, 
ocular and haematological signs/symptoms. aAP were all 
negative and the liver was never affected. After stabilisa-
tion, she was subjected to a regular treatment with pred-
nisolone (10 mg/day) and hydroxychloroquine (400 mg/
day)—with periods of intensification of the immunosup-
pressive dosage due to discoid lupus lesions. The last 
exacerbation of skin lesions was on December 2012. She 
first planned pregnancy in March 2013, under medica-
tion with hydroxychloroquine 400  mg/day, predniso-
lone 2.5 mg/day and acetylsalicylic acid 100 mg/day but 
suffered incomplete miscarriage at 7  weeks gestation, 
requiring uterine curettage. A histopathological analysis 
of the abortion material revealed no signs of thrombosis. 
There was no clinical or laboratory exacerbation of SLE 
during or after pregnancy, apart from the skin lesions 
previously described.
Discussion
SLE associated with pregnancy can lead to maternal, 
obstetric and foetal problems (related to the AID). It 
is agreed that the maternal and foetal prognosis is bet-
ter when the disease is in remission/quiescent for at 
least 6 months prior to conception (Table 2) [17]. This 
patient was in clinical remission at least since 2011. 
The presence of aAP, anti-SSA/Ro or anti-SSB/La anti-
bodies, hypertension or renal impairment, situations 
that comprise a greater risk of complications, were 
excluded. During the 7  weeks of gestation, there was 
no disease activity or lupus flares, although inavailable 
literature, a greater incidence of acute exacerbations 
during pregnancy is described [18], nor were there any 
Table 2 Contraindications for pregnancy in patients with systemic lupus erythematosus (adapted from Andreoli et al. [9])
BP blood pressure, HELLP hemolysis elevated liver enzymes low platelet count.
1. Severe pulmonary hypertension (systolic BP >50 mmHg or symptomatic)
2. Heart failure
3. Severe restrictive lung disease
4. Mild/severe chronic liver failure
5. Treatment with high dosages of corticosteroids
6. Exacerbation in the last 6 months
7. Previous severe preeclampsia or HELLP syndrome, despite treatment with aspirin and heparin
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complications commonly present in pregnant women 
with SLE (hypertension, preeclampsia/eclampsia, pre-
mature rupture of membranes and gestational diabetes, 
which usually appear at later stages [19]). The patient 
eventually had a miscarriage in the first trimester, a 
common complication in SLE [4, 5, 9]. Histopathology 
revealed no signs of thrombosis, which safely excludes 
vascular phenomena associated with APS and/or vas-
culitis, which could foretell a bleaker prognosis for a 
new pregnancy. In terms of treatment (Table  3), cor-
ticosteroids, and hydroxychloroquine were properly 
maintained. The abrupt discontinuation of hydroxychlo-
roquine is one of the main causes of exacerbation of the 
disease during pregnancy [20].
Case 2: antiphospolipid syndrome
A 44 years old, Portuguese citizen, had a first miscarriage 
at 6 months gestation, in 1992, and a second miscarriage 
at 8 months gestation, in 1993. Her first and single deliv-
ery occurred in 1994 and was a preterm of 33 weeks who 
required hospitalisation in Neonatology. She had also a 
history of deep venous thrombosis, with a first episode 
in 2004 and others in 2006 (including brachial region), 
having subsequently initiated treatment with oral anti-
coagulants, which was suspended in late 2012 due to 
methorragias. In January 2013, she was admitted to the 
hospital due to acute myocardial infarction with exten-
sive thrombus in the middle right coronary artery. Tests 
were positive for anti-β-2-glycoprotein (IgG/IgM), anti-
cardiolipin antibodies (IgG/IgM) and ANAs, which led 
to an APS diagnosis and resumption of oral anticoagulant 
medication.
Discussion
APS is probably the AID with the most implications for 
pregnancy. The reason for the referral and follow-up of 
this patient to an AID consultation was not related to the 
pregnancy, but her obstetric history helps support the 
diagnosis. Generally, after the diagnosis of APS and dur-
ing pregnancy, anti-thrombotic therapy is based on low-
molecular-weight heparin (Table  3) [9]. In this patient’s 
case, it should be pointed out that, after the second 
Table 3 Drugs used in the treatment of autoimmune diseases/compatibility with pregnancy (adapted from Andreoli 
et al. [9])
FDA-assigned pregnancy categories (The United States Food and Drug Administration): A controlled studies in humans have failed to demonstrate a risk to the foetus, 
B no evidence of risk for the human species, C Teratogenic—risk to humans cannot be excluded, D clear evidence of risk to the human foetus—risk is acceptable in a 
situation of very high risk for the pregnant woman, in lack of safer alternatives, X Drugs considered unsafe during pregnancy.
NSAID nonsteroidal anti-inflammatory drugs, LMWH low-molecular-weight heparin, IVIG intravenous immunoglobulin, SLE systemic lupus erythematosus.
Drug FDA category Permitted during pregnancy Notes
Prednisolone B Allowed Associated to medical/obstetric complications (mater-
nal diabetes, preeclampsia, premature rupture of 
membranes)
NSAID B/D Allowed; avoid from 3rd trimester onward Risk of premature closure of the arterial duct in the 3rd 
trimester
Hydroxychloroquine C Allowed Discontinuation during pregnancy is associated with 
SLE exacerbations
Azathioprine D Allowed In the smallest therapeutic dosage, if benefits out-
weigh risks
Cyclosporine C Allowed
Tacrolimus C Allowed
Sulfasalazine B Allowed
Methotrexate X Discontinue 3–6 months before a planned pregnancy
Cyclophosphamide D Discontinue at least 3 months before a planned 
pregnancy
Mycophenolatemofetil D Discontinue at least 6 weeks before a planned preg-
nancy
Warfarin D Discontinue after positive pregnancy test Can be used while breastfeeding
LMWH B Allowed Used as primary prevention of thrombotic events  
during the puerperal period
IVIG C Allowed
Rituximab C Discontinue at least 6–12 months before a planned 
pregnancy
Belimumab C Discontinue at least 4 months before a planned 
pregnancy
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miscarriage, APS could have been diagnosed at the first 
thrombotic event.
Case 3: polymyositis
A 31  years old Portuguese citizen with a history of 
PM, diagnosed in 2008 based on a clinical scenario of 
polyarthralgia and myalgia with myositis and a biopsy 
which confirmed the diagnosis. She had a normal cae-
sarean delivery in 2006 and a current pregnancy pro-
gressing uneventfully. PM was diagnosed after the first 
pregnancy. She was treated with high doses of predniso-
lone for 1 year, and was then put on azathioprine. After 
3 years of complete remission and due to her (informed) 
decision to get pregnant, she began a full weaning from 
azathioprine, having stabilised with 10  mg/day predni-
solone. An angiography was performed and excluded 
pulmonary hypertension. She then became pregnant 
and delivered a full term healthy new-born in August 
2013.
Discussion
Given the low incidence (1–9 cases per million) of PM/
DM, its implications for pregnancy are poorly known 
and existing literature consists of mere descriptions 
of cases or series of cases [21]. Fertility is still sub-
ject to speculation. The trend towards lower fertility 
may be more related to prior treatment history [22]. 
The severity of the autoimmune inflammatory activ-
ity affects the foetal prognosis. Complete remission of 
the disease translates into a better outcome of preg-
nancy [23]; otherwise, abortion rates are almost always 
above 50% [24]. This patient’s stability and remission 
were evident, which contributed to the good obstet-
ric development described. Pulmonary hyperten-
sion may be one of the manifestations (although rare, 
~5%) of PM/DM [25], constituting, besides an activ-
ity of the disease, a risk factor for pregnant women 
(10–40% mortality). A decision was made to study the 
presence of this manifestation, despite the absence 
of any cardio- or respiratory symptoms. After it was 
excluded, pregnancy was safely advised. Unlike SLE, 
pregnancy does not induce exacerbations of PM. In 
terms of treatment (Table 3), although azathioprine is 
allowed during pregnancy, it is the team who decides 
on whether to maintain or exclude it [26]; in this case, 
the decision was to replace it with an appropriate dos-
age of corticosteroids.
Case 4: vasculitis—Behcet’s disease
Thirty-eight years old Portuguese citizen with an obstet-
ric history of 3G 2P 1A. She had a first delivery in 2004 
that occurred uneventful. In 2011, she had a miscarriage 
at 7 weeks gestation, with no pathological analysis of the 
abortion material. The third pregnancy was unplanned. 
During the final 15  weeks of gestation, BD was diag-
nosed due to erythema nodosum on limbs and genital 
ulcers (minor criteria) and recurrent oral thrush (major 
criteria), with a 2-year evolution, exacerbated during 
pregnancy. Throughout the entire pregnancy, she was 
only treated with topical betamethasone to control oral 
thrush. The delivery was eutocic, preterm (36  weeks), 
due to premature rupture of membranes. The new-born 
infant required hospitalisation in Neonatology and was 
discharged on day 7. Due to persistent oral thrush and 
postpartum genital ulcers, systemic corticosteroid ther-
apy was initiated (5 mg/day).
Discussion
The BD diagnosis is sometimes suggested by the gynae-
cologist due to the presence of genital ulcers, being oral 
thrush usually underestimated [27, 28]. It is a wide-
spread opinion that pregnancy does not affect the nat-
ural development of BD and vice versa [29], except in 
rarer conditions associated with a worse prognosis for 
pregnancy (vasculopathy, thrombosis and pulmonary 
hypertension), where it has been shown to affect the 
placenta at an early stage [15]. We did not find in the 
literature a description of the relationship between BD 
and preterm delivery as in this case, but we found other 
foetal problems [30]. Immunosuppressive therapy, as 
in the other cases studied, may also have implications. 
BD, and especially severe oral thrush, have an undeter-
mined behaviour during pregnancy, so the treatment 
must be adjusted to each individual using the risk/ben-
efit principle. This patient’s symptoms were only oral 
thrush, and so the treatment adopted was topical. No 
systemic therapy was administered postpartum, con-
sidering the absence of other manifestations (vascular/
uveitis).
Case 5: autoimmune thyroiditis
Thirty-six years old Portuguese citizen, with a history of 
AIT (Hashimoto’s disease) diagnosed in 2006 during her 
first pregnancy. She was medicated with levothyroxine in 
widely variable doses to achieve clinical/laboratory goals. 
Her obstetric history up to the first consultation was 2G 
1P 1A. The first pregnancy had no complications but it 
was eutocic and preterm (34 weeks) and an miscarriage 
occurred during the first trimester in 2012. She was then 
referred to the AID consultation for pathology review 
and due to very high levels of antithyroglobulin and anti-
thyroid peroxidase antibodies and difficult control over 
the thyroid function. After systemic AID was excluded 
and 4  months of clinical stability with antibody regres-
sion, she became pregnant. A new miscarriage occurred 
at 7 weeks gestation.
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Discussion
Upon the diagnosis of organ-specific AID (Hashimoto 
thyroiditis, type 1 diabetes, vitiligo), associated systemic 
diseases must be ruled out. Clinical immunology studies 
have shown that, during pregnancy, initially high levels of 
antithyroid antibodies fall abruptly due to the immune tol-
erance environment [31]. However, AIT is associated with 
higher rates of infertility and early miscarriages, due to the 
associated hormonal changes and instability and higher 
age (the average age of the study groups is above normal 
childbearing age, which is associated with increased obstet-
ric risk), as is the case with this patient. The presence of 
antithyroid antibodies may react against the structures of 
the placenta or fertilized egg and cause problems in embryo 
implantation [32, 33]. This patient’s hormonal instability 
and age were possible causes for the miscarriages.
Conclusions
As described in literature, we found a strong association 
between AIDs and obstetric complications, especially 
with SLE, APS and AIT—of the 12 pregnancies studied, 
50% resulted in miscarriage and 25% in preterm birth. 
However, it is important to point out that these cases 
were already particularly complicated, as they concern 
women who were being followed in specific AID consul-
tations, which excludes simpler cases that do not require 
such specialised care.
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